Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 12, 2013

Leica and Synthon Collaborate on Cancer CDx

  • Leica Biosystems and Synthon Biopharmaceuticals have partnered to develop a companion diagnostic program for targeted cancer therapies. Leica will develop a fully automated tissue-based companion diagnostic test to run on its BOND™ automated advanced staining systems paired with one of Synthon’s antibody-drug conjugates, to enhance the treatment of solid tumors.

    In December 2012, Leica Biosystems teamed up with Galena Biopharma to develop a companion diagnostic for Galena's NeuVax™ (nelipepimut-S or E75) breast cancer therapeutic. Leica's Bond Oracle™ Human Epidermal Growth Factor Receptor 2 (HER2) IHC System companion diagnostic was used to support the selection of the patients for the NeuVax Phase III PRESENT study.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »